Vilon alternatives.
9 compounds compared to Vilon, ranked by published evidence tier and regulatory status, not by what's marketed hardest.
Vilon is a two-amino-acid peptide, Lys-Glu, designed as a minimal synthetic stand-in for the active sequences in thymic preparations such as thymalin. People searching for alternatives are typically trying to move from the most stripped-down member of the Khavinson bioregulator family toward something with a larger evidence base or any regulatory recognition at all, because vilon has none: it is not approved as a drug by the FDA, the EMA, or other major Western regulators, and it is not a dietary supplement. Within this family the step up is thymalin, which is at least a registered medicine in Russia, and then thymosin alpha-1, which is approved in many countries.
Vilon is a synthetic dipeptide, L-lysyl-L-glutamate (Lys-Glu), one of the short peptide bioregulators developed by Vladimir Khavinson's St.
- 01ThymalinD tierResearch / preclinicalthymus peptide extract
Acts through the peptide bioregulators and proposed gene modulation pathway, like Vilon. Research / preclinical.
- 02EpitalonF tierResearch / preclinical
Acts through the peptide bioregulators and proposed gene modulation pathway, like Vilon. Research / preclinical.
- 03PinealonF tierResearch / preclinical
Acts through the peptide bioregulators and proposed gene modulation pathway, like Vilon. Research / preclinical.
- 04
- 05GlutathioneD tierResearch / preclinicalGSH · reduced glutathione
Same category: longevity. Research / preclinical.
- 06MOTS-cF tierResearch / preclinical
Same category: longevity. Research / preclinical.
- 07HumaninF tierResearch / preclinical
Same category: longevity. Research / preclinical.
- 085-Amino-1MQF tierResearch / preclinical
Same category: longevity. Research / preclinical.
- 09FOXO4-DRIF tierResearch / preclinical
Same category: longevity. Research / preclinical.
An “alternative” here means a compound that shares Vilon's mechanism pathway or sits in the same category, not a marketing substitute. Each is ordered by PepCue's evidence tier (a weighted 0–100 score across human data, safety, replication and regulatory clarity), then by whether it's actually approved. This is a research reference, not medical or purchasing advice: an alternative sitting higher on evidence does not mean it's right, safe, or legal for any given use. Reviewed June 1, 2026.
PepCue keeps every compound, dose and lab in one private, provider-ready timeline, whichever one you land on.